Pluristem Therapeutics - New avenues of study

Pluristem continues to advance its PLX technology platform. In a recent paper it investigated the application of these cells for their ability to inhibit tumor growth; it was found that the cells inhibit growth of a mouse xenograft of a triple-negative breast cancer cell line and induced complete remissions in three out of 10 mice. Additionally, PLX-PAD received approval for an expanded access program from the FDA, allowing it to be used to treat critical limb ischemia (CLI) outside the ongoing Phase III clinical study.